中国医药科学
中國醫藥科學
중국의약과학
China Medicine and Pharmacy
2015年
14期
138-140
,共3页
ST段抬高型心肌梗死%冠脉介入术%瑞舒伐他汀%炎性因子
ST段抬高型心肌梗死%冠脈介入術%瑞舒伐他汀%炎性因子
ST단태고형심기경사%관맥개입술%서서벌타정%염성인자
STEMI%Coronary Intervention%Rosuvastatin%Inflammatory factor
目的 探讨瑞舒伐他汀对急性ST段抬高型心肌梗死冠脉介入治疗后动脉粥样硬化、CRP、TNF-α的影响.方法 选取入医院治疗的急性ST段抬高型心肌梗死患者88例患者作为研究对象,入院后均行冠脉介入治疗,采用随机分组将患者分为对照组和观察组,对照组取阿托伐他汀用药,观察组取瑞舒伐他汀用药,观察血脂水平、血浆炎性因子、颈动脉中层厚度(IMT)以及造影结果等.结果 观察组治疗后CRP、TNF-α分别为(3.17±1.56)g/L、(0.98±0.56)μg/L均显著低于对照组,差异具有统计学意义(P<0.05).观察组治疗后TC、TG、LDL-C均显著高于对照组,HDL-C显著低于对照组,差异具有统计学意义(P<0.05).观察组治疗后MLD为(3.12±0.28)mm显著高于对照组,IMT为(0.72±0.35)mm显著低于对照组,差异具有统计学意义(P<0.05).结论 与阿托伐他汀相比,STEMI患者PCI术后取瑞舒伐他汀用药,抗炎、降脂效果更优,可有效抑制支架内再狭窄率.
目的 探討瑞舒伐他汀對急性ST段抬高型心肌梗死冠脈介入治療後動脈粥樣硬化、CRP、TNF-α的影響.方法 選取入醫院治療的急性ST段抬高型心肌梗死患者88例患者作為研究對象,入院後均行冠脈介入治療,採用隨機分組將患者分為對照組和觀察組,對照組取阿託伐他汀用藥,觀察組取瑞舒伐他汀用藥,觀察血脂水平、血漿炎性因子、頸動脈中層厚度(IMT)以及造影結果等.結果 觀察組治療後CRP、TNF-α分彆為(3.17±1.56)g/L、(0.98±0.56)μg/L均顯著低于對照組,差異具有統計學意義(P<0.05).觀察組治療後TC、TG、LDL-C均顯著高于對照組,HDL-C顯著低于對照組,差異具有統計學意義(P<0.05).觀察組治療後MLD為(3.12±0.28)mm顯著高于對照組,IMT為(0.72±0.35)mm顯著低于對照組,差異具有統計學意義(P<0.05).結論 與阿託伐他汀相比,STEMI患者PCI術後取瑞舒伐他汀用藥,抗炎、降脂效果更優,可有效抑製支架內再狹窄率.
목적 탐토서서벌타정대급성ST단태고형심기경사관맥개입치료후동맥죽양경화、CRP、TNF-α적영향.방법 선취입의원치료적급성ST단태고형심기경사환자88례환자작위연구대상,입원후균행관맥개입치료,채용수궤분조장환자분위대조조화관찰조,대조조취아탁벌타정용약,관찰조취서서벌타정용약,관찰혈지수평、혈장염성인자、경동맥중층후도(IMT)이급조영결과등.결과 관찰조치료후CRP、TNF-α분별위(3.17±1.56)g/L、(0.98±0.56)μg/L균현저저우대조조,차이구유통계학의의(P<0.05).관찰조치료후TC、TG、LDL-C균현저고우대조조,HDL-C현저저우대조조,차이구유통계학의의(P<0.05).관찰조치료후MLD위(3.12±0.28)mm현저고우대조조,IMT위(0.72±0.35)mm현저저우대조조,차이구유통계학의의(P<0.05).결론 여아탁벌타정상비,STEMI환자PCI술후취서서벌타정용약,항염、강지효과경우,가유효억제지가내재협착솔.
Objective To explore the influence of atherosclerosis, CRP, TNF-α after coronary intervention treatment of acute ST segment elevation myocardial infarction with rosuvastatin.Methods 88 patients with acute ST segment elevation myocardial infarction (STEMI) in our hospital were selected as research subjects and were received coronary intervention treatment after admission. They were randomly allocated to control group which were given atorvastatin and observation group which were given rosuvastatin. Blood lipid level, plasma inflammatory cytokines, intima-media thickness (IMT) and angiographic results were observed.Results CRP and TNF-α in observation group after treatment were (3.17±1.56) g/L and (0.98±0.56) μg/L, which was significantly lower than those in control group. The difference was statistically significant (P<0.05). TC, TG and LDL-C in observation group were significantly higher than those in control group, and HDL-C in observation group was significantly lower than that in control group after treatment. The difference was statistically significant (P<0.05). MLD in observation group was (3.12±0.28) mm, which was significant higher than that in control group, and IMT was (0.72±0.35) mm which was significantly lower than that in control group after treatment. The difference was statistically significant (P<0.05).Conclusion Comparing with atorvastatin, rosuvastatin has a better curative effect for STEMI patients in anti-inflammatory and anti-hyperlipidemia after PIC, which can inhibit in-stent restenosis rate effectively.
